Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity inducement awards on June 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

The group received an aggregate 6,881 time-based RSUs, vesting in four equal annual installments, subject to continued employment.

News Market Reaction – MDGL

-1.19%

-1.19% Session close to close

In the Jun 5 session, MDGL declined 1.19%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity inducement awards: 6,881 time‑based RSUs granted to 20 new ...

Analysis

This announcement details routine equity inducement awards: 6,881 time‑based RSUs granted to 20 new non‑executive employees under the 2025 Inducement Plan, vesting over four years per Nasdaq Listing Rule 5635(c)(4). It underscores ongoing organizational growth and use of stock‑based compensation tied to continued employment. In context with recent clinical data, conferences, and commercialization updates, investors may track how such grants accumulate versus overall dilution and how they support scaling the MASH franchise.

Key Figures

New employees: 20 employees Inducement RSUs: 6,881 RSUs Vesting schedule: 4 equal installments +1 more

4 metrics

New employees 20 employees Recipients of inducement equity awards on June 1, 2026

Inducement RSUs 6,881 RSUs Time-based restricted stock units granted under 2025 Inducement Plan

Vesting schedule 4 equal installments RSUs vest annually on first through fourth anniversaries of grant

Grant date June 1, 2026 Date RSU inducement awards were granted to new employees

Historical Context

5 past events · Latest: 2026-06-03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-06-03	Conference participation	Neutral	+7.8%	Announcement of presentation slot at major Goldman Sachs health care conference.
2026-05-27	Clinical data update	Positive	+0.7%	Phase 3 and real‑world Rezdiffra data reducing cardiovascular and liver risk markers.
2026-05-21	Inducement grants	Neutral	+0.7%	Equity inducement RSUs to new employees under Nasdaq Listing Rule 5635(c)(4).
2026-05-20	Upcoming data	Positive	-1.3%	Planned EASL 2026 presentations on Rezdiffra’s effects on risk markers.
2026-05-07	Inducement grants	Negative	-4.6%	Larger package of stock options and RSUs granted as inducement awards.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News flow mixes clinical/data updates, conferences, and recurring inducement grants; price reactions often diverge from the apparent importance of the underlying news.

Recent Company History

Over recent months, Madrigal’s news has highlighted Rezdiffra’s commercial and clinical momentum, including Phase 3 and real‑world MASH data and upcoming presentations at major meetings like EASL and the 47th Goldman Sachs Health Care Conference. Alongside this, the company has repeatedly issued equity inducement awards to new employees under its 2025 Inducement Plan. Price reactions have ranged from a 7.79% gain on conference participation to declines after data presentations, showing that routine HR-related grant announcements, like today’s 6,881 RSU grant, occur against a backdrop of more material clinical and commercial milestones.

Key Terms

nasdaq listing rule 5635(c)(4), equity inducement awards, restricted stock units, time-based restricted stock units

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The equity awards were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity inducement awards financial

"it granted equity awards on June 1, 2026 to 20 new non-executive employees as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

restricted stock units financial

"The new employees received, in the aggregate, 6,881 time-based restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

time-based restricted stock units financial

"The new employees received, in the aggregate, 6,881 time-based restricted stock units."

Time-based restricted stock units are a form of employee compensation where individuals are granted company shares that are earned over a set period, often as a reward for staying with the company. These shares typically become fully owned and transferable only after passing specific time milestones, encouraging long-term commitment. For investors, they highlight a company's focus on employee retention and can influence future stock supply and company stability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 6,881 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal Pharmaceuticals (NASDAQ: MDGL) grant on June 1, 2026?

Madrigal Pharmaceuticals granted an aggregate 6,881 time-based restricted stock units to 20 new non-executive employees. According to Madrigal, these awards are equity inducement grants under its 2025 Inducement Plan, designed to support employee recruitment and retention.

Why did Madrigal Pharmaceuticals (MDGL) issue inducement awards under Nasdaq Rule 5635(c)(4)?

Madrigal issued these inducement awards as a material incentive for new employees to accept employment. According to Madrigal, the independent Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4) and the company’s 2025 Inducement Plan.

How do the Madrigal Pharmaceuticals (MDGL) June 2026 RSU grants vest?

The 6,881 restricted stock units vest in four equal annual installments on each of the first through fourth anniversaries of the grant date. According to Madrigal, vesting is conditioned on the employee’s continued employment on each applicable vesting date.

How many employees received Madrigal Pharmaceuticals (MDGL) inducement RSUs in June 2026?

Twenty new non-executive employees received the inducement restricted stock units in June 2026. According to Madrigal, these hires were granted a total of 6,881 time-based RSUs as part of their recruitment packages and long-term equity incentives.

What is Madrigal Pharmaceuticals’ 2025 Inducement Plan for MDGL employees?

Madrigal’s 2025 Inducement Plan allows equity awards to new employees as material inducements to employment. According to Madrigal, the June 1, 2026 grants of 6,881 time-based RSUs to 20 non-executive employees were made under this plan and approved by the Compensation Committee.